• Kala Pharmaceuticals Inc., of Waltham, Mass., presented preclinical data suggesting that topical delivery of a small-molecule receptor tyrosine kinase inhibitor (RTKi) formulated using its mucosal-penetrating particle (MPP) technology enhanced drug levels in the retina.